10th International Congress on Drug Therapy in HIV Infection, 7-–11 November 2010, Glasgow

1 December 2010. Related: Conference reports, Conference index, HIV 10 Glasgow 2010.

The ‘Glasgow conference’ is held every two years and attracts a broad interest from both European and US clinicians and researchers.

This year the conference abstracts are already posted online as a supplement to the Journal of the International AIDS Society (Volume 13, Supplement 4).
http://www.jiasociety.org/supplements/13/S4

In the references to our reports we include both the conference abstract numbers and the IAS publication link.

A PDF file of the abstracts is also available (direct download): http://www.biomedcentral.com/content/files/pdf/1758-2652-13-S4-full.pdf

Approximately 200 posters are online as PDF files, categorised by general topics, and posted to the ‘webcast’ pages of the conference website. A few webcasts are included in this selection.
http://www.hiv10.com/webcastsearch.asp

Reports in this issue include:

• Virological findings from the SARA trial of boosted protease inhibitor monotherapy
• Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
• Estimating the number of people in a country or region with HIV who are undiagnosed and in need of  ART
• High preterm delivery rates associated with initiation of HAART during pregnancy at a London clinic
• Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
• The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure
• Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children
• Efavirenz versus nevirapine based first line treatment in a South African cohort
• GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
• Consensus guidelines recommend routine use of genotypic tropism testing for European patients prior to using maraviroc
• UK studies on bone health: increased fracture rates reported in HIV-positive people
• Muscle weakness or pain analysed as possible raltegravir side effect
• Adding maraviroc does not boost CD4s in randomised trial
• Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
• Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350